# Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

> **NCT01696500** · PHASE3 · COMPLETED · sponsor: **Nihon Pharmaceutical Co., Ltd** · enrollment: 10 (estimated)

## Conditions studied

- Stevens-Johnson Syndrome
- Toxic Epidermal Necrolysis

## Interventions

- **DRUG:** Intravenous immunoglobulin

## Key facts

- **NCT ID:** NCT01696500
- **Lead sponsor:** Nihon Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2014-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696500, "Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01696500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*